Coherus Oncology, Inc. (CHRS) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Coherus Oncology, Inc. (Stock Symbol: CHRS) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry. The organization employs approximately 377 professionals worldwide . The company has established itself as an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Annual Revenue: $35 million generating a -487.8% net profit margin .
Market Capitalization: $143 million - Classified as a small-cap investment offering high growth potential.
Return on Equity (ROE): -299.8% - Below-average shareholder return efficiency, indicating areas for operational improvement.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Coherus Oncology, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Coherus Oncology, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities . , complemented by impressive 443.6% year-over-year cash flow growth. The company maintains a healthy 345.1% gross margin, indicating strong pricing power and operational efficiency.